WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314205
CAS#: 609799-22-6
Description: Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.
MedKoo Cat#: 314205
Name: Tasimelteon
CAS#: 609799-22-6
Chemical Formula: C15H19NO2
Exact Mass: 245.14158
Molecular Weight: 245.32
Elemental Analysis: C, 73.44; H, 7.81; N, 5.71; O, 13.04
Synonym: BMS214778, BMS-214778, BMS 214778, VEC162, VEC-162, VEC 162, Tasimelteon, Hetlioz
IUPAC/Chemical Name: N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide
InChi Key: PTOIAAWZLUQTIO-GXFFZTMASA-N
InChi Code: InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
SMILES Code: CCC(NC[C@H]1[C@H](C2=C3CCOC3=CC=C2)C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 245.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder. Med Lett Drugs Ther. 2014 Apr 28;56(1441):34-5. PubMed PMID: 24759294.
2: Dhillon S, Clarke M. Tasimelteon: first global approval. Drugs. 2014 Mar;74(4):505-11. doi: 10.1007/s40265-014-0200-1. PubMed PMID: 24610704.
3: Traynor K. Tasimelteon approved for circadian disorder in blind adults. Am J Health Syst Pharm. 2014 Mar 1;71(5):350. doi: 10.2146/news140017. PubMed PMID: 24534583.
4: Lankford DA. Tasimelteon for insomnia. Expert Opin Investig Drugs. 2011 Jul;20(7):987-93. doi: 10.1517/13543784.2011.583235. Epub 2011 May 9. Review. PubMed PMID: 21548834.
5: Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs. 2009 Jul;10(7):691-701. PubMed PMID: 19579175.
6: Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Erratum in: Lancet. 2009 Apr 11;373(9671):1252. PubMed PMID: 19054552.
